Aidea Pharma(SH:688488) Zheng Quan Zhi Xing·2025-06-27 16:49Core Viewpoint - The company announced the cancellation of 1.504 million shares of unvested restricted stock from its 2023 stock incentive plan due to the departure of certain incentive targets and unmet performance criteria [6][7]. Group 1: Approval Process of the Stock Incentive Plan - The company held multiple board and supervisory meetings to approve the stock incentive plan and its related documents from August to September 2023 [1][2][3][4]. - Independent directors provided opinions on the incentive plan, and the supervisory board verified the relevant matters [2][4]. Group 2: Details of the Canceled Restricted Stock - A total of 126,000 shares were canceled due to three incentive targets leaving the company [6]. - The remaining shares were canceled because the company did not meet its performance targets for the fiscal years 2023 and 2024, with reported revenues of approximately 411.36 million yuan and 417.80 million yuan respectively [6]. - The HIV drug division also failed to meet its performance targets, with revenues of approximately 73.58 million yuan in 2023 and 149.90 million yuan in 2024 [6]. Group 3: Impact of the Canceled Restricted Stock - The cancellation of the restricted stock will not have a significant impact on the company's financial status or operational results, nor will it affect the stability of the management team or the ongoing implementation of the stock incentive plan [7]. Group 4: Supervisory Board and Legal Opinions - The supervisory board agreed that the cancellation of the restricted stock complies with relevant laws and regulations, and does not harm shareholder interests [7]. - Legal opinions confirmed that the cancellation aligns with the regulations governing stock incentives and necessary disclosure obligations [8].